Lipids and renal disease

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Metabolic Disorders

Background:

• Chronic kidney disease (CKD) is associated with significant alterations in lipid metabolism, including dyslipidemia.
• Dyslipidemia in CKD manifests as abnormal apolipoprotein profiles and elevated plasma lipid levels.
• Elevated cholesterol and triglyceride levels are recognized as independent risk factors for CKD progression in humans.

Purpose of the Study:

• To explore the correlation between dyslipidemia and the progression of renal disease.
• To investigate the potential mechanisms linking lipid levels to kidney damage.
• To evaluate the efficacy of lipid-lowering agents in ameliorating renal disease progression.

Main Methods:

• Review of experimental and clinical studies investigating lipid metabolism in CKD.
• Analysis of data on the impact of high plasma lipid levels on renal disease progression.
• Examination of findings from animal models using lipid-lowering agents.
• Assessment of clinical evidence regarding statin therapy in patients with chronic renal failure.

Main Results:

• Dyslipidemia is a common complication of chronic renal disease, linked to nephrotic syndrome and renal insufficiency.
• High cholesterol and triglyceride levels are independently associated with worsening kidney function.
• Animal studies suggest lipid-lowering agents can reduce glomerular damage and fibrosis.
• Clinical data indicate statin therapy offers benefits to individuals with established chronic renal failure.

Conclusions:

• The relationship between lipid levels and CKD progression is complex and not fully elucidated, with oxidative stress and insulin resistance as potential mediators.
• Lipid-lowering agents demonstrate potential in mitigating renal damage in preclinical models.
• While statins provide benefits in established renal failure, definitive evidence from primary renal outcome studies is required to confirm if lipid reduction slows functional decline in CKD.